Extended Release of ISMN
The technology suggests a pharmaceutical composition useful for extended release of isosorbide mononitrate to an environment of use. More specifically, the present invention relates to a novel pharmaceutical composition for extended release of isosorbide mononitrate, which operates on the principles of diffusion, osmotic pressure, or a combination of both. The use of extended release formulation will provide a more uniform plasma concentration of ISMN for a definite period of time and will tend to avoid the peak and trough effects associated with immediate release formulations. The frequency of daily administration will be reduced and a uniform plasma concentration for a definite period of time will avoid any development of tolerance, resulting in enhanced patient compliance. All the above side effects of ISMN and the fact that the half-life of the drug is around 4 to 5 hours, the advantages of a pharmaceutical composition for extended release of ISMN, appear evident.
Sector: Fluid systems and components for general use
Country: India
Area of Application: ISMN,isosorbide mononitrate
Keywords: ISMN
Advantages: Extended release of ISMN Reduces frequency of daily administration. Uniform plasma concentration of ISMN for a definite period of time. Enhanced patient compliance.
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection: Patent
Technical specifications:
Transfer Terms: Technology Licensing
Target Countries: India
Estimated cost (US$):
Upload any relevant document:
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
City: Ahmedabad
Country: India
Zip/Pin Code: 380054
Contact Technology Provider
Technology offer
Interested in this technology?
Request further information or explore potential cooperation with the technology provider.
Technology request
Can you help meet this technology need?
Share a relevant technology, expertise or partnership opportunity with APCTT.